Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Table 1

Comparison of pathological characteristics between the two groups.

	Control group	Observation group	value
Age	49 ± 5.3	48 ± 4.6	0.945
TNM stage			0.564
III	44 (55%)	47 (59%)
IV	36 (45%)	33 (41%)
Pathological type			0.215
Serous papillary cystadenocarcinoma	69 (86%)	75 (94%)
Mucinous papillary cystadenocarcinoma	11 (14%)	5 (6%)
Differentiated			0.341
Poorly differentiated	46 (58%)	40 (50%)
Moderately differentiated	28 (35%)	32 (40%)
Highly differentiated	6 (7%)	8 (10%)
CA125			0.645
≤35 U/ml	21 (26)	25 (31)
>35 U/ml	59 (74)	55 (69)